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We determined risk factors associated with persistent carriage of methicillin-resistant Staph-
ylococcus aureus (MRSA) among 102 patients enrolled in a double-blind, placebo-controlled
trial of nasally administered mupirocin ointment. MRSA decolonization was unsuccessful in
77 (79%) of 98 patients who met the criteria for evaluation. By univariate analysis, 4 variables
were found to be associated with persistent MRSA colonization ( for all 4): absence ofP ! .1
mupirocin treatment, previous fluoroquinolone therapy, >2 MRSA-positive body sites, and
low-level mupirocin resistance. After multivariable Cox proportional hazards modeling, the
presence of >2 positive body sites (adjusted hazard ratio [AHR], 1.7; 95% confidence interval
[CI], 1.0–2.9) and previous receipt of a fluoroquinolone (AHR, 1.8; 95% CI, 1.0–3.3) were
independently associated with MRSA persistence, whereas nasal mupirocin tended to confer
protection (AHR, 0.6; 95% CI, 0.4–1.0). Low-level mupirocin resistance was observed in 9
genotypically different MRSA strains and was not independently associated with chronic
MRSA carriage (AHR, 1.5; 95% CI, 0.9–2.5). Our findings suggest that multisite MRSA
carriage and previous receipt of a fluoroquinolone are independent risk factors for persistent
MRSA colonization.
Mupirocin ointment was introduced in the United Kingdom
in the mid-1980s and has subsequently been demonstrated to be
highly effective in the eradication of nasal carriage of both meth-
icillin-sensitive and methicillin-resistant strains of Staphylococcus
aureus [1]. However, reports of mupirocin-resistant strains of
staphylococci have continued to appear since they were first de-
scribed in 1987 [2]. Usage patterns that have promoted the emer-
gence of mupirocin resistance include application of mupirocin
ointment for long periods of time and its indiscriminate use
within an institution [1]. The general consensus is that high-level
resistant strains (MIC, 1256 mg/mL) cannot be eradicated with
mupirocin, whereas the clinical significance of low-level mupi-
rocin resistance (LMR) remains dubious [3, 4].
We recently reported the results of a double-blind, placebo-
controlled trial that demonstrated the failure of nasal mupirocin
ointment to eliminate multisite carriage of methicillin-resistant
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S. aureus (MRSA) [5]. Surprisingly, by unadjusted statistical
analysis, we observed a significant association between LMR
and subsequent treatment failure in patients in both study arms.
In the present analysis, we determined independent risk factors
associated with persistent MRSA carriage and further assessed
the significance of LMR, adjusted for confounding variables.
Methods
A complete description of the patients and methods has been
reported elsewhere [5]. In brief, from October 1995 through Sep-
tember 1997, 102 patients with MRSA carriage and without signs
of active infection were randomly assigned to receive either placebo
(51 patients) or nasally applied mupirocin (51 patients) for MRSA
eradication. All patients received daily baths or showers with 4%
chlorhexidine soap (Hibiscrub; Zeneca Pharma, Cergy, France) for
whole-body washing, that included the hair and the perianal region.
At baseline, 55% of patients had MRSA colonization simulta-
neously at different body sites. The primary study end point was
the efficacy of nasally applied mupirocin in the eradication of
MRSA carriage at any body site. Failure was defined as the re-
covery of a positive MRSA culture result from any body site within
1 month after randomization [5].
Possible predictors of persistent MRSA carriage explored in the
present analysis were as follows: age, sex, underlying diseases and
comorbidities, nutritional and functional status, device exposure (uri-
nary catheters, central venous catheters, or both), antibiotic exposure
during the present admission, previous MRSA history, colonization
site, number of positive sites, transfer from another hospital or long-
term care facility, presence or absence of exposure to mupirocin in
the study, mupirocin resistance, and infection of control measures
such as contact isolation. Each patient was assessed for the presence
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Figure 1. Kaplan-Meier probability estimates for the 30-day failure
rate of all patients ( ) according to (A) treatment assignment;n p 98
(B) the number of methicillin-resistant Staphylococcus aureus carriage
sites at baseline; and (C) fluoroquinolone exposure before study
enrollment.
of the following underlying conditions: coronary heart disease (re-
sulting in permanent alteration of the cardiac function [New York
Heart Association classes III or IV]), diabetes mellitus (requiring
either oral therapy or insulin treatment), pulmonary disease (resulting
in functional disability and/or requiring chronic bronchodilator ther-
apy), gastrointestinal disease (e.g., hepatitis or gastroduodenal ul-
cers), renal disease (chronic underlying renal disorder), cancer (ma-
lignant disease process causing permanent disability), and neurologic
disease (stroke or other active neurologic conditions with permanent
disability). In addition, we classified the patients’ functional status
as belonging to 1 of 3 categories: (1) requires minimal assistance in
performing activities of daily living; (2) requires moderate, occasional
assistance and has sporadic bladder incontinence; and (3) requires
heavy, permanent assistance to perform activities of daily living and
has chronic incontinence of the bladder and the bowel.
Antimicrobial susceptibility testing was performed according to
the National Committee for Clinical Laboratory Standards [6], by
use of disk diffusion methodology. The zone diameter breakpoints
for both isolates susceptible to mupirocin and isolates resistant to
mupirocin were >14 and <13 mm, respectively [7]. In addition,
MICs of mupirocin were determined by E test methodology (AB
Biodisk, Solna, Sweden). The MIC breakpoints for mupirocin were
<4 mg/L for susceptible isolates, 8–64 mg/L for isolates with low-
level resistance, 128–256 mg/L for isolates with intermediate-level
resistance, and >500 mg/L for isolates with high level resistance
[8]. S. aureus ATCC 29223 was used as a quality control strain for
disk diffusion testing and determination of MICs. Molecular typing
of MRSA isolates was performed by means of contour-clamped
homogenous electric-field electrophoresis [9].
We expressed continuous variables as the mean (5 SD) or as the
median and interquartile range if their distribution was skewed. Base-
line characteristics were compared by use of the Student’s t test or
Wilcoxon test, for continuous variables, and by use of the x2 test or
Fisher’s exact test for assessment of differences in proportions.
For all patients meeting the criteria for evaluation, observation
continued from randomization for at least 30 days, or until treat-
ment failure or loss to follow-up, if either occurred in the interim.
Kaplan-Meier failure curves were drawn and compared between
different groups by use of the log-rank test; we counted patients
who were positive with MRSA after randomization as having treat-
ment failures, and the remainder were considered censored as of
the last day of observation. We looked for independent risk factors
of persistent MRSA carriage by use of a stepwise Cox proportional
hazards model [10]. This model assessed the effect of each predictor
on the hazard rate of failure over time, after adjustment for other
factors and after allowing for censoring because of discharge,
death, or loss to follow-up [11]. We used graphical methods to
check the proportional hazards assumption and searched for effect
modification by including appropriate interaction terms [12]. All
continuous variables were categorized or dichotomized because
none of them satisfied the linearity assumption. Variables for which
P was !.15 were entered into the multivariable analysis. Confound-
ing was tested by examination of effect sizes (b coefficients) with
and without inclusion of the potential confounder in the model
[13]. Variables that caused substantial confounding (change in b
coefficients, >20%) were included in the final model. The strength
of the association between prognostic variables and the outcome
of interest was expressed as a hazard ratio (HR), and the corre-
sponding 95% CIs were calculated.
To identify risk factors predicting MRSA recolonization after
the end of the chlorhexidine baths or showers, we further divided
follow-up into 2 periods. For the late period, a Cox proportional
hazards model was created with all observations starting on day
10 (the end of chlorhexidine body washing); it excluded all patients
having a time to MRSA detection of <9 days.
All statistical tests were 2-tailed. was considered signif-P ! .05
icant. Statistical packages used were SPSS, version 8.0 (SPSS, Chi-
cago) and Stata, version 6.0 (Stata, College Station, TX).
Results
Of the 102 patients enrolled in the study, 4 were excluded
(because of major protocol violations in the first 24 h); there-
fore, at the time of randomization, there were 98 patients who
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Table 1. Comparison of patients with and without persistent carriage of meth-







(n p 21) P
Female sex 36 (47) 4 (19) .02
Mean age 5 SD, y 75.7 5 13.9 67.5 5 20.1 .09
Mean weight 5 SD, kg 67.6 5 19.3 69.9 5 17.3 .6
Previous hospitalizations, mean 5 SD 6.7 5 5.7 3.5 5 5.3 .2
Direct admission from home 45 (58) 10 (48) .4
Comorbidities, mean 5 SD 3.3 5 2.1 3.5 5 2.0 .7
Underlying conditions
Coronary heart disease 19 (25) 5 (24) 1
Diabetes mellitus 25 (32) 7 (33) 1
Pulmonary disease 18 (23) 6 (29) .6
Gastrointestinal disease 16 (21) 6 (29) .4
Neurologic disease 26 (34) 5 (24) .2
Renal disease 11 (14) 2 (10) .7
Cancer 9 (12) 3 (14) 1
Functional status
Minimal assistance required 42 (55) 9 (43) .3
Moderate assistance required 14 (18) 3 (14) 1
Permanent assistance required 21 (27) 9 (43) .2
Supplemental enteral nutrition 12 (16) 5 (24) .5
Duration of known MRSA carriage,
median (interquartile range), d 11 (180) 35 (379) .7
Previous mupirocin exposure 18 (23) 4 (19) .7
Contact isolation 69 (90) 19 (90) 1
Urinary catheter 20 (26) 5 (24) .8
Central venous catheter 8 (10) 3 (14) .7
Mupirocin study exposure 36 (47) 12 (57) .4
Any previous antibiotic exposure dur-
ing the present admission 31 (40) 11 (52) .3
Recent receipt of fluoroquinolonesa 19 (25) 0 (0) .006
Low-level mupirocin resistance at the
end of treatment 24 (31) 0 (0) .001
Colonized body sites at baseline .04
1 30 (39) 14 (67)
2 25 (32) 5 (24)
>3 22 (29) 2 (9)
Number of colonized sites, mean 5 SD 1.90 5 0.82 1.41 5 0.67 .01
Nasal carriage 48 (62) 9 (43) .1
Groin/perianal carriage 31 (40) 6 (29) .3
Skin carriage other than groin/perianal 38 (49) 11 (52) .8
Urinary tract colonization 16 (21) 4 (19) .9
NOTE. Data are no. (%) unless otherwise indicated.
a During the present admission before inclusion in the study. Ciprofloxacin, 14 patients;
norfloxacin, 5 patients.
were only colonized with MRSA and who met the criteria for
evaluation. Of these patients, 77 (79%) had persistent MRSA
carriage at the end of follow-up. Important characteristics of
patients with and without treatment failure are summarized in
table 1.
As shown in figure 1A, the probability of MRSA persistence
30 days after randomization was 0.75 for the patients in the
mupirocin-treated group and 0.82 for the patients in the pla-
cebo-treated group (by log-rank test; ). The medianP p .097
interval to failure was 12 days (95% CI, 11–13 days) for the
placebo group and 14 days (95% CI, 9–19 days) for the mu-
pirocin group. Figure 1B displays the Kaplan-Meier curves ac-
cording to the number of MRSA carriage sites at baseline.
By univariate Cox regression analysis, we found that 4 var-
iables were associated with persistent MRSA carriage (P ! .1
for all 4; table 2): previous fluoroquinolone therapy (HR, 1.6;
95% CI, 0.9–2.7; figure 1C), >2 body sites positive for MRSA
(HR, 1.8; 95% CI, 1.1–2.9), absence of mupirocin treatment
(HR, 1.5; 95% CI, 1.0–2.3), and LMR (HR, 1.6; 95% CI,
1.0–2.6). After adjustment for confounding variables (urinary
tract carriage and mupirocin treatment before study entry), the
presence of >2 body sites positive for MRSA (adjusted HR
[AHR], 1.7; 95% CI, 1.0–2.9; ) and previous receiptP p .035
of a fluoroquinolone (AHR, 1.8; 95% CI, 1.0–3.3; )P p .048
were independently associated with MRSA persistence, whereas
treatment with nasal mupirocin tended to confer protection
(AHR, 0.6; 95% CI, 0.4–1.0; ; table 3). Although weP p .066
observed differing probabilities of cumulative failure (figure 2)
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Table 2. Simple Cox regression analysis indicating risk factors for persistence of methicillin-





ratio 95% CI P
Demographic characteristics
Female sex 40 36 (90) 1.31 0.83–2.05 .29
Age 175 y 53 42 (79) 1.04 0.66–1.63 .86
Previous hospitalization 77 66 (86) 1.20 0.63–2.28 .57
Underlying conditions and health status
Coronary heart disease 24 19 (79) 1.11 0.66–1.87 .69
Diabetes mellitus 32 25 (78) 1.12 0.62–2.05 .73
Pulmonary disease 24 18 (75) 0.88 0.49–1.57 .69
Neurologic disease 31 26 (84) 0.98 0.61–1.58 .96
Gastrointestinal disease 22 16 (73) 1.05 0.70–1.58 .79
Cancer 12 9 (75) 1.02 0.51–2.04 .90
13 comorbidities 42 31 (74) 0.78 0.49–1.23 .38
Bad functional status requiring permanent
assistance 30 21 (70) 0.82 0.50–1.34 .43
Supplemental enteral nutrition 17 12 (71) 0.75 0.41–1.41 .38
Clinical characteristics
Newly discovered MRSA status (!2 weeks) 50 42 (84) 1.38 0.88–2.17 .16
Exposure to nasal mupirocin during an-
other previous hospitalization 22 18 (82) 0.79 0.46–1.34 .38
Mupirocin study exposure 48 36 (75) 0.67 0.43–1.05 .08
Low-level mupirocin resistance 24 24 (100) 1.59 0.95–2.59 .08
Previous exposure to any antibiotic agent
during the present admission 42 31 (74) 0.86 0.55–1.35 .51
Recent receipt of fluoroquinolones 19 19 (100) 1.57 0.93–2.66 .09
Contact isolation 88 69 (78) 1.05 0.52–2.12 .83
Urinary catheter 25 20 (80) 1.07 0.64–1.79 .68
Central venous catheter 11 8 (73) 0.70 0.36–1.46 .34
Microbiologic characteristics
>2 distinct colonized body sites 54 47 (87) 1.80 1.13–2.88 .01
Nasal carriage 57 48 (84) 1.42 0.88–2.28 .16
Groin/perianal carriage 37 31 (84) 1.31 0.82–2.08 .27
Skin site carriage other than groin/perianal 49 38 (78) 0.89 0.57–1.40 .75
Urinary tract carriage 20 16 (80) 1.09 0.64–1.88 .75
Table 3. Multivariable Cox regression model showing independent




hazards ratio 95% CI P
>2 distinct MRSA body sites 1.73 1.04–2.87 .035
Recent exposure to fluoroquinolones 1.81 1.01–3.26 .048
Absence of mupirocin therapy 1.55 0.97–2.47 .066
Low-level mupirocin resistance 1.48 0.87–2.52 .146
Urinary tract carriagea 1.57 0.84–2.96 .161
No previous exposure to mupirocina 1.41 0.79–2.51 .251
a Confounding variables.
for mupirocin-treated patients with and without LMR strains
(log-rank test, ), LMR was not independently associ-P p .08
ated with treatment failure in the multivariate model (AHR,
1.5; 95% CI, 0.9–2.5; ).P p .15
In addition, we examined risk factors for late failure, con-
sidering 2 distinct periods (see the “Methods” section). The
prognostic significance of previous fluoroquinolone therapy
(AHR, 2.4; 95% CI, 1.2–4.6; ) and multiple body sitesP p .009
positive for MRSA at study entry (AHR, 1.9; 95% CI, 1.1–3.3;
) appeared to be more pronounced late in the follow-P p .026
up. Moreover, urinary tract carriage of MRSA (AHR, 2.2; 95%
CI, 1.0–4.6; ) and LMR (AHR, 1.8; 95% CI, 1.0–3.3;P p .041
) became independent risk factors in this model.P p .045
A total of 42 patients (43%) had received 79 different anti-
biotic agents during the present admission before they entered
the study. Fluoroquinolones were prescribed for 19 patients
(ciprofloxacin, for 14, and norfloxacin, for 5); amoxicil-
lin–clavulanic acid, for 15; imipenem, for 11; cephalosporins,
for 8; glycopeptides, for 7; clindamycin, for 5; trimethoprim-
sulfamethoxazole, for 5; and other agents, for 9. No association
was found between previous antibiotic exposure and persistent
MRSA carriage with the exception of recent fluoroquinolone
therapy, which was prescribed for a median of 7 days (range,
2–34 days). Susceptibility analysis of MRSA isolates from pa-
tients previously exposed to fluoroquinolones revealed resis-
tance to this class of antibiotic agents in all cases.
Overall, 46 MRSA isolates with LMR were observed among
27 patients. MICs of mupirocin were as follows: for 5 isolates,
64 mg/L; for 4 isolates, 48 mg/L; for 5 isolates, 32 mg/L; for
11 isolates, 24 mg/L; and for 21 isolates, 16 mg/L. No isolate
showed high-level resistance to mupirocin. At the time of study
enrollment, low-level resistant strains were documented in 23
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Figure 2. Kaplan-Meier curves showing the probability over time
of methicillin-resistant Staphylococcus aureus persistence for patients
only in the mupirocin-treated group ( ), stratified by the presencen p 48
or absence of low-level mupirocin resistance. R, resistance.
patients. Four patients acquired low-level resistance during mu-
pirocin therapy and 3 patients in the placebo group lost their
mupirocin-resistant strains.
All 46 isolates showing LMR were available for molecular
subtyping. LMR was observed in 9 genotypically distinct
MRSA strains. The most frequent profile was recovered in 8
patients, followed by 2 distinct profiles, each of which involved
5 patients, and 6 other profiles that involved 1–3 patients.
Discussion
We examined risk factors for persistent MRSA carriage in 98
patients with MRSA colonization who were enrolled in a double-
blind, placebo-controlled trial of nasal mupirocin. The proba-
bility of persistent MRSA colonization was almost 2 times greater
among patients with 11 colonized body site and among patients
who had recently received fluoroquinolones. LMR tended to in-
crease the risk of persistent MRSA carriage, whereas nasal mu-
pirocin treatment tended to confer protection. These findings may
help explain, at least in part, the observed differences in the
efficacy of topical eradication treatment in various groups of
patients with MRSA carriage. More importantly, these data
could help to improve existing control strategies for patients with
MRSA colonization. Finally, our study results support the ob-
servation that exposure to fluoroquinolones increases MRSA ad-
hesion and carriage, and the results further suggest that LMR
may play a more important role in the failure to eradicate MRSA
carriage than was previously thought.
Our discovery of a trend toward treatment failure in cases
with LMR stands in contrast to the common view that LMR
has no clinical impact. The latter concept is based on the finding
that low-level resistant strains colonizing the nasal cavity can
be eradicated with high concentrations of mupirocin and that
clinical failures were only rarely observed when treating isolates
demonstrating LMR [3, 4, 14]. However, no controlled study
has proven this hypothesis. Anecdotally, Gaspar et al. [15] have
concluded from an outbreak in Spain that MRSA colonization
at multiple body sites was clinically more important than LMR
in the failure of topical treatment. We confirmed this finding
by performing multivariable modeling and extended it by show-
ing that the identification of LMR was an independent risk
factor for late occurrence of failure. However, a limitation of
the present analysis was that the small number of LMR cases
limited the precision of the calculated HRs and CIs. Therefore,
we cannot confidently rule out the influence of chance alone
on this worrisome finding. In addition, the evidence of a sta-
tistical association between LMR and MRSA persistence does
not prove causality, although we could exclude that 1 predom-
inant MRSA clone that biased our results. Further studies in
this direction are urgently needed, but our findings should gen-
erate broader concern about the clinical significance of LMR.
The association between the administration of antibiotics and
the occurrence or persistence of MRSA is complex. Although
the relative participation of cross-transmission and antimicrobial
selection pressure in MRSA dissemination remains to be deter-
mined, Monnet [16] recently described several lines of evidence
to support the existence of an association between MRSA car-
riage and antimicrobial utilization. Fluoroquinolones in partic-
ular are prone to increase the occurrence and persistence of mul-
tiresistant staphylococci [16–21]. In 2 reports of MRSA outbreaks
in Germany, a country with a high rate of ciprofloxacin use,
thorough investigation of multiple risk factors showed that pre-
vious fluoroquinolone exposure was an independent risk factor
for carriage of MRSA [18, 19]. A national surveillance study
from Belgium demonstrated a direct association between MRSA
occurrence and the use of fluoroquinolones [22].
Consistent biological models can explain these epidemiologic
findings. Hoiby et al. [23] showed the rapid development of
methicillin-resistant Staphylococcus epidermidis in the axilla and
nostrils of volunteers receiving ciprofloxacin. Colonization by
such multiresistant S. epidermidis strains lasted, on average,
130 days after ciprofloxacin treatment was terminated. Al-
though these authors did not report on the findings for MRSA,
ciprofloxacin is likely to have the same effect on patients car-
rying S. aureus [16, 17, 24, 25]. Finally, 2 studies performed by
Bisognano et al. [26, 27] showed the increased expression of
fibronectin-binding proteins by fluoroquinolone-resistant S. au-
reus exposed to subinhibitory levels of ciprofloxacin, leading to
increased adhesion and prolonged carriage of S. aureus. There-
fore, our discovery of a possible association between previous
fluoroquinolone exposure and persistent MRSA colonization
is consistent with other microbiological evidence and warrants
confirmation in larger epidemiologic studies.
A limitation of the analysis was that the sparse data for some
variables precluded a more detailed examination. For instance,
only 1 patient was infected with HIV, and only 2 patients re-
quired hemodialysis. Nevertheless, the observed rate of MRSA
persistence was large enough to perform valid multivariable
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Cox modeling and did not compromise the accuracy and pre-
cision of the generated HRs [28].
The presented risk factor analysis offers important infor-
mation about and strong quantitative estimates of the proba-
bility of persistent MRSA carriage in hospitalized patients, ex-
tending earlier findings [29]. Our data will help explain some
of the disparities in reported success rates of mupirocin and
other topical eradication treatments, and these insights may
lead to the development of more-effective MRSA control strat-
egies. Finally, these data highlight what type of patients may
be least likely to benefit from a topical eradication regimen.
Future studies that build on these results may consider new
preventive strategies related to the number of carriage sites and
to patients’ previous exposure to fluoroquinolones, and, thus,
they may be able to better target patients most likely to benefit
from topical eradication therapy.
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